OBSOLETE: Mycobacterium xenopi infection

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

3 events
Jun 2025Biomarkers of Phage Treatment Response in NTM and Other Infections

NYU Langone Health

TrialRECRUITING
May 2021Hypertonic Saline for MAC

Oregon Health and Science University — PHASE4

TrialRECRUITING
Dec 1992

Mycobutin: FDA approved

Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

2

Copay cards

Copay Assistance2

Mycobutin

Adria Laboratories, Inc.

OpenContact for details

Rifabutin

Pfizer

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Mycobutin

(Rifabutin)Orphan drug

Adria Laboratories, Inc.

Rifamycin Antimycobacterial [EPC]

Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammal...

Approved Dec 1992FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

2 active trials
1Phase 4
1Unknown
2Total recruiting
Search clinical trials for OBSOLETE: Mycobacterium xenopi infection

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Mycobacterium xenopi infection.
Search PubMed for OBSOLETE: Mycobacterium xenopi infection

Browse all OBSOLETE: Mycobacterium xenopi infection news →

Specialist Network

No specialists currently listed for OBSOLETE: Mycobacterium xenopi infection.

View all OBSOLETE: Mycobacterium xenopi infection specialists →

Quick Actions